Shanghai Yifang Biological Products Co., Ltd. (688382.SH) issued an announcement, the company collaborated with China Grand Pharmaceutical and Healthcare Holdings Limited (referred to as "...
Wise Finance and Economics APP news, Shanghai Yifang Biological Products Co., Ltd. (688382.SH) issued an announcement, the 1st innovative drug developed in collaboration with China Grand Pharmaceutical and Healthcare Holdings Limited (referred to as "Zhengda Tianqing"), Goserelin Tablets (trade name: Anfangning) has been approved for market launch by the National Medical Products Administration. The drug is used to treat late-stage non-small cell lung cancer (NSCLC) adult patients who have undergone at least one systemic treatment and have the KRAS G12C mutation. Goserelin (D-1553) is a novel and efficient KRAS G12C inhibitor independently developed by the company, used for the treatment of various cancers such as non-small cell lung cancer and colorectal cancer with KRAS G12C mutation.
